Protagonist Therapeutics

PTGX

United States

protagonist-inc.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PTGX · Stock Price

USD 98.85+55.88 (+130.04%)

Market Cap: $6.3B

Historical price data

Overview

Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.

Inflammation & ImmunologyHematologyMetabolic Diseases

Technology Platform

Proprietary peptide discovery and engineering platform featuring Vectrix™ technology, designed to overcome historical challenges of oral bioavailability and stability to create novel peptide drugs.

Pipeline

14 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Open-label rusfertide	Polycythemia Vera	Phase 3
Placebo + Rusfertide	Polycythemia Vera	Phase 3
PTG-300	Polycythemia Vera	Phase 2
PTG-300	Hereditary Hemochromatosis	Phase 2
PTG-300	β-thalassemia	Phase 2

Opportunities

Near-term commercialization of rusfertide in polycythemia vera and royalty streams from the Janssen-partnered icotrokinra provide a path to profitability.

The proprietary platform offers a long-term opportunity to disrupt large markets like obesity with novel, optimized oral and injectable peptide drugs.

Risk Factors

The company faces significant competition in all core therapeutic areas and is dependent on partner Janssen for the commercial success of its lead asset, icotrokinra.

Clinical, regulatory, and commercial execution risks remain for its wholly-owned pipeline candidates.

Competitive Landscape

Protagonist competes with large pharma and biotech in crowded but high-value markets (I&I, obesity). Its differentiation lies in its platform's ability to generate oral peptides with best-in-class potential, such as icotrokinra versus other IL-23 inhibitors, and first-in-class mechanisms like rusfertide in hematology.